BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NewLink Genetics Raises $43.4 Million in IPO


11/11/2011 9:40:44 AM

AMES, Iowa, Nov 11, 2011 (GlobeNewswire via COMTEX) -- NewLink Genetics Corporation announced today the initial public offering of 6,200,000 shares of its common stock at a price of $7.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on November 11, 2011 under the trading symbol "NLNK." NewLink has granted the underwriters a 30-day option to purchase up to 930,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.

Stifel Nicolaus Weisel and Canaccord Genuity Inc. are acting as joint book-running managers for the offering, and Robert W. Baird & Co. Incorporated and Cantor Fitzgerald & Co. are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 10, 2011. This offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; and from Canaccord Genuity Inc., 99 High Street, 12th Floor, Boston, MA 02110, or by calling (800) 225-6201.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. For more information please visit us at www.linkp.com .

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: NewLink Genetics Corporation



Read at BioSpace.com
Read at CBS News
Read at Wall Street Journal
Read at Street Insider
Read at RTT News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES